There were 1,489 press releases posted in the last 24 hours and 457,581 in the last 365 days.

Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum

/EIN News/ --

The Company’s Proposed Pharma Grade Version of Tauri-Gum™ is Being Developed Specifically to Target: Patients Subjected to Ongoing Chemotherapy Treatment (the “Indication”)

NEW YORK, NY, Dec. 18, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire-- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnologies initiatives, today announced that it has entered into a Master Services Agreement (the “Agreement”) with North Carolina based Clinical Strategies & Tactics, Inc. (“CSTI”) to resume the clinical development of its proposed “Anti-Nausea” pharmaceutical grade version of Tauri-Gum™. CSTI will largely be focusing its efforts on the following: Pharmaceutical Development Strategy (“I.”), Commercialization Strategy (“II.”), and Funding Strategy (“III.”).  The Company will be working closely with CSTI’s Founder & CEO, JoAnn C. Giannone (“Ms. Giannone”), who has over 25 years’ experience effectively leading companies through the drug and medical device development process (Prior to founding CSTI, Ms. Giannone held leadership positions with Johnson & Johnson and Pharmacia).  The Company intends to fund the entirety of this Agreement, before the end of Calendar 2020.


I.              Pharmaceutical Development Strategy

  • Clinical and Non-Clinical safety and efficacy strategy/studied (e.g., purpose, type, estimated sample size, treatment duration, etc.)
  • Product development and manufacturing strategy (e.g., physical product formulation, scale up, testing, packaging, and analytical testing to meet stage-appropriate regulatory requirements)
  • Regulatory submission strategy with defined regulatory milestones (e.g., pre-IND, IND, NDA, etc. and any special designations)
  • Overall development costs and funding needs by milestone
  • Overall development timeline
  • Elements of the development program that should be prioritized for development

II.            Commercialization Strategy

  • Market Assessment
  • Competitive Analysis
  • Product Differentiation & Market Advantage
  • Target Product Profile (“TPP”)
  • Market Research
  • Pricing
  • Reimbursement
  • Draft Forecast

III.           Funding Strategy

  • Non-Dilutive Options
  • Commercial Partners, Venture Funds, Universities, Philanthropic Opportunities, Patient Advocacy Groups, etc.


The delivery system for this proposed Pharmaceutical version is a modified version (substantially higher concentration of CBD) of the existing “Tauri-Gum™” chewing gum formulation based on continued research and development. 

On March 18, 2020 the Company announced that it had filed a Provisional U.S. Patent covering its Pharmaceutical grade version of Tauri-Gum™. This patent application, filed with the United States Patent & Trademark Office (“U.S.P.T.O.”), is titled: “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT.”
U.S. Provisional Patent Application No. 62/990,709

Below - CSTI Corporate Website:



Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Tauri-Gum™ Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: Please visit our corporate website, for additional information, as well as inquiries, at

Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   

On October 6, 2020, the Company announced that it has been approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4)

On October 7, 2020 the Company disclosed a Strategic Alliance with Think BIG, LLC, Social Impact Startup Founded by CJ Wallace, Son of Christopher “The Notorious B.I.G.” Wallace.

The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER -- Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.


Tauriga Sciences, Inc.

555 Madison Avenue, 5th Floor

New York, NY  10022

Chief Executive Officer

Mr. Seth M. Shaw


cell # (917) 796 9926

Instagram: @taurigum

Twitter: @SethMShaw

Corp. Website:

E-Commerce Website:

Primary Logo